

23rd October, 2026

To,
The Manager - Corporate Relationship
Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: NSE - KILITCH

Sub: Press Release

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release relating to the proposed divestment of entire stake in the overseas subsidiary which we shall be releasing immediately after intimation to the exchanges.

Request you to take note of the same and acknowledge the receipt.

Thanking you,

Yours' Faithfully,

For Kilitch Drugs (India) Limited

MUKUND
PRATAPRAI MEHTA

Digitally signed by MUKUND
PRATAPRAI MEHTA
Date: 2026.10.23 15:09:00 +05'30'

Mukund Mehta
Managing Director



Kilitch Drugs to Divest Entire Stake in Ethiopian Subsidiary in US\$14 Million Transaction

- *Proposed divestment to enable capital reallocation towards higher-growth opportunities in India, debt repayment and expansion of core pharmaceutical business*
- *Company to maintain commercial presence in Ethiopia through a proposed long-term supply and technical services agreement*

Mumbai, October 23, 2026: Kilitch Drugs (India) Limited (BSE: KILITCH | 524500 | INE729D01010), a pharmaceutical company specialising in the manufacturing and distribution of high-quality parenteral formulations, oral solid dosage forms and effervescent products, today announced it's a strategic divestment of its entire shareholding in its Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), to HarmeeCare Pharmaceuticals, an Ethiopian state-owned enterprise, in a transaction valued at US\$14 million.

The proposed transaction, approved by the company's Board of Directors forms part of Kilitch Drugs' broader strategy to optimise its business portfolio, strengthen financial flexibility and accelerate investments in its pharmaceutical manufacturing operations in India. The divestment will enable capital reallocation towards higher-growth opportunities in India, debt repayment and expansion of core pharmaceutical business

The company intends to utilise the net proceeds towards reducing existing borrowings, lowering finance costs and supporting the phased expansion of its new manufacturing facility at Pen, Maharashtra.

The Pen facility represents a significant step in the company's next phase of growth. Building on its established expertise in aseptic manufacturing, Kilitch Drugs plans to manufacture liquid injectable vials, lyophilised (freeze-dried) injectable vials and ophthalmic eye drops at the facility, and to develop and manufacture GLP-1 (Glucagon-Like Peptide-1) therapies, positioning it to participate in the fast-growing GLP-1 segment as patents on key molecules expire across various international markets. It also intends to pursue EU GMP (European Union Good Manufacturing Practice) and PIC/S (Pharmaceutical Inspection Co-operation Scheme) accreditations as part of its strategy to expand its presence in regulated export markets. All of these plans are subject to applicable regulatory approvals.

Commenting on the proposed transaction, Bhavin Mehta, Whole-Time Director, Kilitch Drugs (India) Limited, said: "Our focus is on building the next phase of Kilitch Drugs' growth by strengthening our manufacturing capabilities and expanding our presence in high-potential pharmaceutical segments. The strategic divestment of our Ethiopian subsidiary will enable us to unlock capital, strengthen our balance sheet and accelerate our expansion plans in India. With our new Pen facility coming on stream in phases, we see significant opportunities to leverage our manufacturing experience, participate in emerging therapy segments such as

GLP-1 and deepen our presence in international regulated markets. We believe these initiatives will position Kilitch Drugs for sustainable, long-term growth.”

Meanwhile, to maintain its commercial presence in Ethiopia, Kilitch Drugs proposes to enter into a long-term supply and technical services agreement with HarmeeCare Pharmaceuticals. The arrangement is expected to support the continued operations of the Ethiopian manufacturing facility while providing opportunities for an ongoing commercial relationship in the region.

The divestment is expected to be completed by January 31, 2027, subject to shareholder approval, applicable regulatory requirements and completion of the necessary transaction documentation.

With a sharpened focus on domestic manufacturing, expanding international opportunities and greater financial flexibility, Kilitch Drugs aims to strengthen its position in the pharmaceutical sector and create long-term value for its stakeholders.

About Kilitch Drugs (India) Limited

Kilitch Drugs (India) Limited is a Mumbai-based pharmaceutical company with over three decades of experience in pharmaceutical manufacturing, including aseptic formulations. The company manufactures and markets pharmaceutical products for domestic and international markets. With expanding manufacturing capabilities in Maharashtra, Kilitch Drugs is focused on enhancing its product portfolio, exploring emerging therapeutic opportunities and strengthening its presence in regulated international markets.